Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.51 |
| ▸ | PI4KA | P42356 | 2/20 | 0.51 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.51 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.51 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.51 |
| ▸ | DPP4 | P27487 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.51 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.51 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.51 |
| ▸ | GAPDH | P04406 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | STAT6 | P42226 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.51 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25428843 | 0.80 | AHCY (0.46) | ADORA3ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL29436002 | 0.79 | ADORA3 (0.55) | ADORA3ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL1276079 | 0.76 | TK1 (0.46) | ADORA3MEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL8632632 | 0.76 | ADORA3 (0.51) | ADORA3ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL28836965 | 0.71 | ADORA3 (0.63) | ADORA3ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL29904279 | 0.71 | ADORA3 (0.63) | ADORA3ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL580610 | 0.70 | ADORA2A (0.64) | ADORA3ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL31620053 | 0.69 | ADORA3 (0.49) | ADORA3ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL28413958 | 0.68 | ADORA2A (0.62) | ADORA3ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL27003093 | 0.68 | AHCY (0.63) | ADORA3ADORA2AADORA1PI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 534 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348903-A1 | OLIGONUCLEOTIDES | Hudson Institute of Medical Research (AU) | 2023-11-02 | — | — | US | claimed |
| CN-115916978-A | Oligonucleotides | 哈德森医学研究所 | 2023-04-04 | — | — | CN | claimed |
| US-10344261-B2 | Immunomodulatory conjugates | ASCEND BIOPHARMACEUTICALS LTD (AU) | 2019-07-09 | — | — | US | claimed |
| US-20150030626-A1 | IMMUNOMODULATORY CONJUGATES | Ascend Biopharamaceuticals Ltd (AU) | 2015-01-29 | — | — | US | claimed |
| EP-2776070-A1 | IMMUNOMODULATORY CONJUGATES | Ascend Biopharmaceuticals Ltd (AU) | 2014-09-17 | — | — | EP | claimed |
| WO-2013067597-A1 | IMMUNOMODULATORY CONJUGATES | ASCEND BIOPHARMACEUTICALS PTY LTD (AU) | 2013-05-16 | — | — | WO | claimed |
| US-20260069717-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12502431-B2 | Delivery and formulation of engineered nucleic acids | MODERNATX, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-12467050-B2 | Methods and compositions for engineering synthetic bioswitches for remote control of biological activity | GEORGIA TECH RESEARCH CORPORATION (US) | 2025-11-11 | — | — | US | disclosed |
| US-12448622-B2 | Oligonucleotides | Hudson Institute of Medical Research (AU) | 2025-10-21 | — | — | US | disclosed |
| US-20250302925-A1 | CONJUGATED CRISPR-CAS COMPLEXES | SYNTHEGO CORPORATION | 2025-10-02 | — | — | US | disclosed |
| US-12419957-B2 | Delivery and formulation of engineered nucleic acids | MODERNATX, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-12416032-B2 | Synthetic self-amplifying MRNA molecules with secretion antigen and immunomodulator | SunVax mRNA Therapeutics Inc. (US) | 2025-09-16 | — | — | US | disclosed |
| CN-1122667-C | Process for preparing N6-substituted deaza-adenosine derivatives | AVENTIS PHARM PROD INC (US) | 2003-10-01 | — | — | CN | disclosed |
| CN-1383427-A | Process for preparing N6-substituted deaza-adenosine derivatives | AVENTIS PHARM PROD INC (US) | 2002-12-04 | — | — | CN | disclosed |
| CN-1333773-A | Process for preparing N6-substituted deaza-adenosine derivatives | AVENTIS PHARM PROD INC (US) | 2002-01-30 | — | — | CN | disclosed |
| US-5817786-A | Single-stranded labelled oligonucleotides of preselected sequences | MOLECULAR BIOSYSTEMS, INC. (US) | 1998-10-06 | — | — | US | disclosed |
| US-5668266-A | Synthesis of single-stranded labelled oligonucleotides of preselected sequence | SYNGENE, INC. (US) | 1997-09-16 | — | — | US | disclosed |
| US-5541313-A | Single-stranded labelled oligonucleotides of preselected sequence | MOLECULAR BIOSYSTEMS, INC. (US) | 1996-07-30 | — | — | US | disclosed |
| US-4948882-A | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis | SYNGENE, INC. (US) | 1990-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344261-B2 | Immunomodulatory conjugates | CLEC4M, TLR3, CD74 | ADORA3 2908/4885ADORA2A 1926/4885ADORA1 2962/4885 |
| US-20150030626-A1 | IMMUNOMODULATORY CONJUGATES | CLEC4M, TLR3, CD74 | ADORA3 2908/4885ADORA2A 1926/4885ADORA1 2962/4885 |
| US-12419957-B2 | Delivery and formulation of engineered nucleic acids | RNMT, HNRNPAB, HNRNPA2B1 | ADORA3 2836/4885ADORA2A 1890/4885ADORA1 2700/4885 |
| US-20260069717-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | RNMT, RNGTT, NSUN2 | ADORA3 335/4885ADORA2A 393/4885ADORA1 681/4885 |
| US-20250302925-A1 | CONJUGATED CRISPR-CAS COMPLEXES | DCLRE1B, MRE11, FEN1 | ADORA3 4091/4885ADORA2A 3894/4885ADORA1 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.